Hematology › Forums › Hematology MCQ discussion forum › NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs › Reply To: NEET SS Clinical Hematology 2020 Telegram Group Discussion MCQs
August 20, 2020 at 8:54 pm
#4176
Participant
35. Which of the following is not a factor bypass agent. Factor bypass agents are standard of care for bleeding hemophilia pateints with inhibitor ?
[1] FEIBA
[2] rFVII
[3] Emicizumab
[4] Idracizumab
Answer = [4] Idracizumab
Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.